Celator Claims Phase III Vyxeos Victory In AML

Celator Pharmaceuticals Inc. more than quadrupled in after-hours trading on March 14 after the company reported Phase III overall survival (OS) data for Vyxeos (CPX-351) that could support US and EU approvals for the first new acute myeloid leukemia (AML) therapy in almost 40 years.